Lowest Price Guaranteed
Slides
200
Last Updated
July 2026
View Count
12316
The global 3D printed drugs market size is valued at USD 281.63 million in 2024 and is poised to reach at USD 605.09 million by 2035, representing a CAGR of 7.20% during the forecast period.
 |
To learn more about this report, request a free sample copy
3D printed drugs also known as 3D printed pharmaceuticals are personalized medication that are created by using 3D printing technology. In pharmaceutical industry, 3D printed drugs emerge as a cutting-edge solution with tailored release profile, precise dosage and composite structure that are difficult to achieve through traditional drug development process. These innovative printed medications have a porous structure for easy dispersal into the mouth, eliminating the requirement of swallowing high dosage of medication.
It is worth noting here that 3D printing technology allows drug developers to modify the form, size and rate of distribution of different type of medication. This drug formulation customization is crucial to meet the patient’s individual requirement, reducing side effects and improving patient compliance. The market for 3D printed drugs is propelled by the growing demand for personalized therapeutics across wide pool of patient population, particularly geriatric patients with chronic diseases. Furthermore, the growing approval of the 3D printed drugs from the FDA has accelerated the manufacturing of these medications to help patients manage their chronic condition.
Spritam, developed by Aprecia Pharmaceuticals, became the first 3D printed drug to be launched in the US in March 2016, as an anti-epileptic medication. Additionally, in February 2024, Triastek (Chinese 3D Printing drug firm) announced that its T22 3D printed gastric retention product has received investigational new drug (IND) clearance from the FDA. This 3D printed drug has become the first of its kind medication to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Driven by the growing approval from the FDA, various industry players active in this field are accelerating their R&D efforts to enhance the development of 3D printing drug technological innovations in 3D printing.
Owing to the increasing approval from the FDA and rising partnerships between industrial players, we believe that the 3D printed drugs market will grow exponentially during the forecast period. Additionally, the market will remain investible during the forecast period driven by several factors such as rising demand for less expensive, tailored therapeutic drugs and growing applicability of 3D printing in pharmaceutical industry.
The 3D printed drugs market report covers in-depth information of the leading industrial players who are active across various segments of the growing industry as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2035 | USD 605.09 Million | |
| Market CAGR | 7.20% | |
| Type of Dosage Form |
|
|
| Types of Technology |
|
|
| Type of Application |
|
|
| Type of End User |
|
|
| Key Geographical Region |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of the 3D printing drugs market report was to estimate the current market size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
Additionally, the market report features the likely distribution of market based on the basis of type of dosage form (3D printed tablets, 3D printed capsules, 3D printed multi drug implants, 3D printed nanoparticles, 3D printed solutions and other 3D printed drug dosage forms), type of technology (inkjet 3D printed technologies, direct write 3D printed technologies, zipdose 3D printed technologies, thermal inkjet 3D printed technologies, 3D printed technologies based on fused deposition modeling, powder bed 3D printed technologies, stereo lithography 3D printed technologies and semi solid extrusion 3D printed technologies), type of application (neurology, orthopedic, dental and other applications), type of end user (hospitals & clinics, research laboratories and other end users), geographical region (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players.
To account for the uncertainties associated with the development of 3D printed technology and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.
Based on the type of dosage form, the global 3D printed drugs market is segmented into 3D printed tablets, 3D printed capsules, 3D printed multi drug implants, 3D printed nanoparticles, 3D printed solutions and other 3D printed drug dosage forms. According to our projection, currently 3D printed tablets hold the highest share of the market and is likely to remain dominant during the upcoming years. This can be attributed to the growing approval of 3D printed tablets with improved bioavailability, and widespread applicability of 3D printed tablets. Furthermore, the increasing demand for advanced personalized therapeutics with tailored drug dosage has further contributed to the growth of 3D printed tablets.
However, it is important to highlight that the customized 3D printed drugs require advanced drug delivery systems for targeted delivery. Driven by the increasing requirement of drug delivery technologies, the 3D printed nanoparticles segment is likely to grow at a higher CAGR during the forecast period. The growth of 3D printed nanoparticles has been further bolstered by the growing usage of nanoparticles in gene therapy, vaccine development and targeted cancer treatment.
This segment highlights the distribution of 3D printed drugs market on the basis of technology into inkjet 3D printed technologies, direct write 3D printed technologies, zipdose 3D printed technologies, thermal inkjet 3D printed technologies, 3D printed technologies based on fused deposition modeling, powder bed 3d printed technologies, stereo lithography 3D printed technologies and semi solid extrusion 3D printed technologies. Presently, zipdose 3D printing technologies occupy the highest share of the market. This dominance is primarily due to the fact that 3D printed drug based on zipdose technology has been approved by the FDA. This technology supports the manufacturing of on-demand therapeutic drugs such as Spritam 3D printed drug approved by the FDA.
In addition, the growing incidence of dysphagia among geriatric population has surged the demand for 3D printing of pharmaceuticals that are easy to swallow and have higher efficacy. However, in the long run, inkjet printer technology is expected to grow at a higher CAGR during the forecast period. This can be attributed to the fact that inkjet 3D printed technologies have been widely adopted by pharmaceutical industry for depositing three-dimensional shapes within solid dosage forms.
The global 3D printed drugs market is distributed across various type of applications, such as neurology, orthopedic, dental and other applications. According to our projection, currently neurology accounts for the highest share (52%) of the market. This dominance is due to the launch of approved SPRITAM® (levetiracetam) 3D printed drug to treat patients with epilepsy. the growing prevalence of neurological disorders such as Alzheimer’s disease and Parkinson’s disease across the globe has catered the attention of industrial players to develop more 3D printed drugs for patients with neurological disorders.
On the other hand, orthopedic procedures are complex & tough, and new approaches are needed to overcome a slew of known issues and better patient outcomes. In addition, complications, particularly the high rate of infection, frequently result in extended patient suffering and functional loss. Thus, orthopedic drugs can be used to combat postoperative infections, hence, propelling the market growth.
The global 3D printed drugs market is categorized on the basis of end user into hospitals & clinics, research laboratories and other end users. According to our projection, presently hospitals & clinics occupy the highest share (52%) of the market. Hospitals & clinics are the primary user of 3D printed drugs to treat chronic diseases. Furthermore, healthcare experts are preferring personalized pharmaceutical drugs for the treatment of patients with chronic conditions has accelerated the growth of this segment.
Additionally, the 3D printer can be easily installed in the hospitals & clinics for the development of on-demand therapeutic drugs specifically with low stability.
However, it is important to highlight here that research laboratories segment is anticipated to grow at a higher CAGR driven by the rising demand for 3D printed drug technology for additive manufacturing and rapid prototyping. In addition, 3D printed drug technology enable the fabrication of personalized therapeutic drug delivery that has complex geometrics and multiple releasing profiles for research purposes.
Based on the geographical region, the global market is distributed across various regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Currently, North America holds 40% 3D printed drugs market share. This highest share can be attributed to the growing prevalence of chronic diseases and presence of advanced healthcare infrastructure. Further, the increasing usage of advanced 3D printed technologies by the industrial players has contributed to the growth of this region.
However, in Asia-Pacific, the 3D printed drugs market is estimated to grow at a higher CAGR during the forecast period. This is primarily due to the significant advances in 3D printed technologies and healthcare infrastructure. Furthermore, the supportive research and development frameworks in Asian countries like India, China and Australia has accelerated the market growth in this region.
The “3D Printed Drugs Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study on the current market landscape and future potential of developing 3D printed drugs and technologies, over the next decade. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.
Presently, the market landscape has the presence of several new entrants. Driven by the growing preferences for personalized therapeutics to treat patients with chronic conditions, several industrial players have taken strategic initiatives followed by collaborations and partnerships. However, the primary focus is on product portfolio enhancement and technological innovations. The larger players are entering the market through partnership and collaborations. In July 2024, BioNTech SE entered into an agreement with Triastek for development of 3D printed RNA therapeutics for oral delivery.
In another such collaboration, Adare Pharma announced collaboration with Laxxon in September 2024 to leverage state-of-the-art cGMP facilities of Adare Pharma and 3D printing technology of Laxxon’s to development innovative 3D printed oral dosage forms. This 3D printed oral dosage form features advanced geometric internal structures along with heterogeneous distribution of active ingredients and improved bioavailability.
Overall, the market seems highly competitive, featuring the presence of several small, mid-sized and large companies with required expertise in manufacturing advanced 3D printed drugs. As more industrial players continue to increase their efforts for developing 3D printed drugs, we believe the market will remain competitive during the forecast period.
Several factors that are propelling growth in this market include growing preferences for personalized medicine and increasing research initiatives. 3D printing technology such as inkjet technology enable printing of drugs with improved solubility and bioavailability. Furthermore, the drugs can be tailored by using innovative 3D printing technology according to the patient’s individual requirement which further increased the demand for 3D printing of drugs during the projected period.
Additionally, the market has been further propelled by the growing research activities by both academic and industry players for the development of 3D printed drugs. In October 2024, researchers based at Texas A&M University announced the development of a 3D printed tablet for treatment of toxoplasmosis in pediatric patients. The 3D printed tablets will be manufactured at Reynolds Medical Sciences Building at the university campus.
Despite the growing demand, the global market has witnessed several challenges that may impede the market growth. Some of the potential challenges includes lack of regulatory guidelines for the development of 3D printed drugs and limited availability of approved drugs. It is worth noting here that lack of availability of specific guidelines and limited drugs approval may create challenges in the approval of 3D printed drugs. Additionally, the limited availability of drug materials to be inked with 3D printing technologies can hinder market growth during the forecast period.
Several other factors that may impact the 3D printed drugs market growth include the development of advanced 3D printing technologies, software and need for excipients for optimizing mechanical properties of drugs.
Currently, the market players are focusing on making considerable investments in this field for technological innovations. However, the current focus of the industry stakeholders is on the development of latest technologies such as fused deposition modeling, injection modeling, and laser sintering. These advanced 3D printing technologies enable the development of personalized medicine that address the patients’ specific requirements.
University / academic institutions have proven to be leading such technological developments. At University of Nottingham’s Centre for Additive Manufacturing, a team of researchers are working on a Multi-Material InkJet 3D Printing (MM-IJ3DP) technology that aims to print tablets that allow controlled release of drugs.
Furthermore, several researchers are forging partnership agreements to increase their efforts for the development of advanced 3D printed technologies and 3D printed drugs. For instance, in February 2024, 3D Systems (US based 3D printer manufacturer) successfully launched industry’s first multi-material, monolithic (one-piece), jetted 3D printed denture solution for printing drugs. Likewise, several industrial leaders are taking considerable initiatives to drive innovations in this field, which is anticipated to be a key 3D printed drugs market growth factor.
Currently, North America is dominating the 3D printing industry and the trend is likely to remain unchanged during the forecast period. The dominance is likely to be the result of growing technological innovations and availability of advanced healthcare infrastructure. Moreover, North America has the presence of several well-established companies who are presently focusing on 3D printing technologies and 3D printed drugs. The North American 3D printed drugs market is also propelled by the growing incidence of chronic diseases that has led rises the demand for personalized medicines.
In addition to North America, the market for 3D printed drugs will show lucrative growth potential in Asia-Pacific. Asian countries like India, Australia and China are emphasizing on advancements in healthcare infrastructures and cutting-edge 3D printing technologies. Additionally, strong emphasize of industrial players on research and development of 3D printed drugs and supportive clinical development framework further supports the growth of this market in this region.
The global market for 3D printed drugs is currently valued at USD 281.63 million. Driven by the growing demand for tailored therapeutic drugs, this market is expected to reach at USD 605.09 million by 2035, representing a higher CAGR of 7.20% during the forecast period. There is opportunity for indications where the commercially available drugs are expensive and drugs have to be compounded for specific populations, such as elderly or pediatrics.
Examples of key players engaged in this domain (which have also been captured in this report) include 3DR HOLDINGS, 3D Systems, Anatomics, AstraZeneca, Aprecia Pharmaceuticals, Affinity Therapeutics, Biomedical Modeling, BioDuro, Bioduro, Cyfuse Biomedical, Cycle Pharmaceuticals, Envision, Extend Biosciences, FabRx, GlaxoSmithKline, Hewlett Packard Caribe, Materialize, Merck, Organovo Holdings, Osmotica Pharmaceuticals, Proto Labs, Rokit Healthcare, Renishaw, Stratasys, Siemens, TVASTA, Triastek, Yissum and Zortrax.
Several recent developments have taken place in the field of 3D printed drugs. We have outlined some of these recent initiatives below.